(Q40621694)

English

Specific Antibody Responses to Vaccination with Bivalent CM235/SF2 gp120: Detection of Homologous and Heterologous Neutralizing Antibody to Subtype E (CRF01.AE) HIV Type 1

scientific article published on September 1, 2003

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

Specific Antibody Responses to Vaccination with Bivalent CM235/SF2 gp120: Detection of Homologous and Heterologous Neutralizing Antibody to Subtype E (CRF01.AE) HIV Type 1 (English)

1 reference

10.1089/088922203769232601

https://api.crossref.org/works/10.1089/088922203769232601

26 March 2024

1 reference

based on heuristic

inferred from title

1 reference

10.1089/088922203769232601

https://api.crossref.org/works/10.1089/088922203769232601

26 March 2024

John R. Mascola

5

object named as

John Mascola

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

Deborah L. Birx

17

object named as

Deborah L Birx

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

15

object named as

Merlin L Robb

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

1

object named as

Jerome H Kim

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

Victoria R Polonis

8

object named as

Victoria Polonis

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

Punnee Pitisuttithum

2

object named as

Punnee Pitisuttithum

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

Robert McLinden

9

object named as

Robert McLinden

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

Thippawan Chuenchitra

4

object named as

Thippawan Chuenchitra

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

author name string

Chirasak Kamboonruang

3

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

Anna Sambor

10

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

Benjaluck Phonrat

12

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

Kittipong Rungruengthanakit

13

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

Anne-Marie Duliege

14

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

John McNeil

16

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

Thai AIDS Vaccine Evaluation Group

18

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

John Mascola

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14585211

26 March 2024

Sarah S. Frankel

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14585211

26 March 2024

Mark S. DeSouza

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14585211

26 March 2024

Victoria Polonis

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14585211

26 March 2024

Arthur E. Brown

11

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14585211

26 March 2024

language of work or name

1 reference

based on heuristic

inferred from title

publication date

1 September 2003

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

full work available at URL

http://www.liebertpub.com/doi/pdf/10.1089/088922203769232601

1 reference

10.1089/088922203769232601

https://api.crossref.org/works/10.1089/088922203769232601

26 March 2024

AIDS Research and Human Retroviruses

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

19

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

9

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

807-816

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

Global burden of the HIV pandemic

2

1 reference

10.1089/088922203769232601

https://api.crossref.org/works/10.1089/088922203769232601

26 March 2024

Changes in sexual behavior and a decline in HIV infection among young men in Thailand

3

1 reference

10.1089/088922203769232601

https://api.crossref.org/works/10.1089/088922203769232601

26 March 2024

Neutralization of multiple laboratory and clinical isolates of human immunodeficiency virus type 1 (HIV-1) by antisera raised against gp120 from the MN isolate of HIV-1

4

1 reference

10.1089/088922203769232601

https://api.crossref.org/works/10.1089/088922203769232601

26 March 2024

Safety and immunogenicity of a fully glycosylated recombinant gp160 human immunodeficiency virus type 1 vaccine in subjects at low risk of infection. National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group Network.

5

1 reference

10.1089/088922203769232601

https://api.crossref.org/works/10.1089/088922203769232601

26 March 2024

HIV-1MN recombinant glycoprotein 160 vaccine-induced cellular and humoral immunity boosted by HIV-1MN recombinant glycoprotein 120 vaccine. National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group.

7

1 reference

10.1089/088922203769232601

https://api.crossref.org/works/10.1089/088922203769232601

26 March 2024

Modulation of immunologic responses to HIV-1MN recombinant gp160 vaccine by dose and schedule of administration. National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group

8

1 reference

10.1089/088922203769232601

https://api.crossref.org/works/10.1089/088922203769232601

26 March 2024

Safety and immunogenicity of a candidate HIV-1 vaccine in healthy adults: recombinant glycoprotein (rgp) 120. A randomized, double-blind trial. NIAID AIDS Vaccine Evaluation Group

10

1 reference

10.1089/088922203769232601

https://api.crossref.org/works/10.1089/088922203769232601

26 March 2024

Studies of high doses of a human immunodeficiency virus type 1 recombinant glycoprotein 160 candidate vaccine in HIV type 1-seronegative humans. The AIDS Vaccine Clinical Trials Network.

11

1 reference

10.1089/088922203769232601

https://api.crossref.org/works/10.1089/088922203769232601

26 March 2024

Safety and immunogenicity of Env 2-3, a human immunodeficiency virus type 1 candidate vaccine, in combination with a novel adjuvant, MTP-PE/MF59. NIAID AIDS Vaccine Evaluation Group

12

1 reference

10.1089/088922203769232601

https://api.crossref.org/works/10.1089/088922203769232601

26 March 2024

Induction of HIV-1-neutralising and syncytium-inhibiting antibodies in uninfected recipients of HIV-1IIIB rgp120 subunit vaccine

13

1 reference

10.1089/088922203769232601

https://api.crossref.org/works/10.1089/088922203769232601

26 March 2024

A phase I/II trial of HIV SF2 gp120/MF59 vaccine in seronegative Thais

14

1 reference

10.1089/088922203769232601

https://api.crossref.org/works/10.1089/088922203769232601

26 March 2024

AIDSVAX (MN) in Bangkok injecting drug users: a report on safety and immunogenicity, including macrophage-tropic virus neutralization

15

1 reference

10.1089/088922203769232601

https://api.crossref.org/works/10.1089/088922203769232601

26 March 2024

Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Ev

16

1 reference

10.1089/088922203769232601

https://api.crossref.org/works/10.1089/088922203769232601

26 March 2024

Neutralization of a clade B primary isolate by sera from human immunodeficiency virus-uninfected recipients of candidate AIDS vaccines

17

1 reference

10.1089/088922203769232601

https://api.crossref.org/works/10.1089/088922203769232601

26 March 2024

Antigenic implications of human immunodeficiency virus type 1 envelope quaternary structure: oligomer-specific and -sensitive monoclonal antibodies

20

1 reference

10.1089/088922203769232601

https://api.crossref.org/works/10.1089/088922203769232601

26 March 2024

HIV-1 nomenclature proposal

21

1 reference

10.1089/088922203769232601

https://api.crossref.org/works/10.1089/088922203769232601

26 March 2024

Development of bivalent (B/E) vaccines able to neutralize CCR5-dependent viruses from the United States and Thailand

23

1 reference

10.1089/088922203769232601

https://api.crossref.org/works/10.1089/088922203769232601

26 March 2024

Wide distribution of two subtypes of HIV-1 in Thailand

24

1 reference

10.1089/088922203769232601

https://api.crossref.org/works/10.1089/088922203769232601

26 March 2024

Genetic variants of HIV-1 in Thailand

25

1 reference

10.1089/088922203769232601

https://api.crossref.org/works/10.1089/088922203769232601

26 March 2024

Two antigenically distinct subtypes of human immunodeficiency virus type 1: viral genotype predicts neutralization serotype

29

1 reference

10.1089/088922203769232601

https://api.crossref.org/works/10.1089/088922203769232601

26 March 2024

Neutralizing monoclonal antibodies block human immunodeficiency virus type 1 infection of dendritic cells and transmission to T cells.

30

1 reference

10.1089/088922203769232601

https://api.crossref.org/works/10.1089/088922203769232601

26 March 2024

Safety and immunogenicity of combinations of recombinant subtype E and B human immunodeficiency virus type 1 envelope glycoprotein 120 vaccines in healthy Thai adults.

31

1 reference

10.1089/088922203769232601

https://api.crossref.org/works/10.1089/088922203769232601

26 March 2024

Neutralizing antibodies from the sera of human immunodeficiency virus type 1-infected individuals bind to monomeric gp120 and oligomeric gp140

33

1 reference

10.1089/088922203769232601

https://api.crossref.org/works/10.1089/088922203769232601

26 March 2024

Neutralization of Divergent HIV-1 Isolates by Conformation-Dependent Human Antibodies to Gp120

34

1 reference

10.1089/088922203769232601

https://api.crossref.org/works/10.1089/088922203769232601

26 March 2024

Vaccine-induced antibodies to the native, oligomeric envelope glycoproteins of primary HIV-1 isolates

35

1 reference

10.1089/088922203769232601

https://api.crossref.org/works/10.1089/088922203769232601

26 March 2024

A human immunodeficiency virus prime-boost immunization regimen in humans induces antibodies that show interclade cross-reactivity and neutralize several X4-, R5-, and dualtropic clade B and C primary isolates

36

1 reference

10.1089/088922203769232601

https://api.crossref.org/works/10.1089/088922203769232601

26 March 2024

Human immunodeficiency virus type 1 neutralization is determined by epitope exposure on the gp120 oligomer

39

1 reference

10.1089/088922203769232601

https://api.crossref.org/works/10.1089/088922203769232601

26 March 2024

Replicative function and neutralization sensitivity of envelope glycoproteins from primary and T-cell line-passaged human immunodeficiency virus type 1 isolates.

41

1 reference

10.1089/088922203769232601

https://api.crossref.org/works/10.1089/088922203769232601

26 March 2024

Differential role of V3-specific antibodies in neutralization assays involving primary and laboratory-adapted isolates of HIV type 1.

42

1 reference

10.1089/088922203769232601

https://api.crossref.org/works/10.1089/088922203769232601

26 March 2024

V3 variability can influence the ability of an antibody to neutralize or enhance infection by diverse strains of human immunodeficiency virus type 1

46

1 reference

10.1089/088922203769232601

https://api.crossref.org/works/10.1089/088922203769232601

26 March 2024

Public health. AIDS vaccine trial produces disappointment and confusion

47

1 reference

10.1089/088922203769232601

https://api.crossref.org/works/10.1089/088922203769232601

26 March 2024

Identifiers

10.1089/088922203769232601

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40621694&oldid=2111552468"